Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$218.06
+1.1%
$232.15
$160.86
$250.74
$13.45B0.39546,697 shs405,008 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.80
-1.1%
$70.38
$38.57
$84.94
$13.23B0.972.71 million shs1.55 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.19
+0.6%
$22.90
$13.15
$27.72
$12.01B1.696.41 million shs4.51 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$51.89
+0.6%
$50.50
$26.27
$59.87
$3.97B0.12511,503 shs362,761 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+2.77%-1.48%-9.28%-4.59%+25.55%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.22%+0.33%+2.43%-2.68%+72.98%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+5.02%-2.39%+12.17%+5.03%+69.10%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+4.69%+4.77%-13.28%+12.67%+70.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$218.06
+1.1%
$232.15
$160.86
$250.74
$13.45B0.39546,697 shs405,008 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.80
-1.1%
$70.38
$38.57
$84.94
$13.23B0.972.71 million shs1.55 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.19
+0.6%
$22.90
$13.15
$27.72
$12.01B1.696.41 million shs4.51 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$51.89
+0.6%
$50.50
$26.27
$59.87
$3.97B0.12511,503 shs362,761 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+2.77%-1.48%-9.28%-4.59%+25.55%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.22%+0.33%+2.43%-2.68%+72.98%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+5.02%-2.39%+12.17%+5.03%+69.10%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+4.69%+4.77%-13.28%+12.67%+70.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$295.3935.46% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.85
Moderate Buy$89.5934.12% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2016.56% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.89
Moderate Buy$60.8617.28% Upside

Current Analyst Ratings Breakdown

Latest KNSA, ASND, BBIO, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform
6/8/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
UpgradeHold (C+)Buy (B-)
6/3/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageBuy$104.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOverweight$94.00 ➝ $98.00
5/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingBuy$110.00
5/26/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
DowngradeOutperformMarket Perform
5/19/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageNeutral$82.00
5/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Initiated CoverageBuy$355.00
5/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UpgradeBuyStrong-Buy
5/18/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
UpgradeStrong SellHold
5/15/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingSell (D)
(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M16.70N/AN/A($2.97) per share-73.42
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M26.06N/AN/A($10.77) per share-6.20
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.56$2.34 per share10.36$13.18 per share1.84
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$677.56M5.89$0.80 per share64.98$7.44 per share6.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$8.6725.1520.30N/A57.87%N/A-8.37%8/6/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A290.43N/A-124.42%N/A-65.81%8/4/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.831.58-4.95%7.42%3.66%8/6/2026 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$0.9057.3130.52N/A9.69%13.26%9.86%7/28/2026 (Estimated)

Latest KNSA, ASND, BBIO, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.21$0.32+$0.11$11.29$362.47 million$285.45 million
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
4/28/2026Q1 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.18$0.27+$0.09$0.27$206.11 million$214.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.79
1.00
0.72
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.79
3.33
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.86 million167.99 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22076.94 million36.95 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$218.06 +2.46 (+1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$218.30 +0.24 (+0.11%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$66.80 -0.75 (-1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$66.81 +0.01 (+0.01%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.19 +0.14 (+0.59%)
Closing price 03:59 PM Eastern
Extended Trading
$24.18 -0.02 (-0.07%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$51.89 +0.31 (+0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$51.81 -0.08 (-0.15%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.